RINGQUEST: Exploring Understudied Genitourinary Tumors with Sacituzumab Tirumotecan; a Single-arm, Basket, Phase II Study.

2026-526048-10-00 · tracked via the Priya Life Science EU tracker

Sponsor

Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard

Sponsor type

Patient organisation/association

Therapeutic area

Neoplasms

Decision date

24/09/2026

Enrollment target

100

Sites

Spain

Condition studied

Papillary Renal Cell Carcinoma (pRCC) Variant Histology Urothelial Carcinoma (VH-UC)

Investigational medicinal product(s)

MK-2870

Eligibility

Age group

18-64 years, 65+ years

Sex

Female, Male

Primary endpoint

ORR according to RECIST 1.1 criteria.

Endpoint detail

DoR: time from first documented complete or partial response until radiological progression (RECIST v1.1) or death, whichever comes first., PFS: time from first dose of study treatment to radiologically confirmed progression (RECIST v1.1) or death from any cause., OS: time from first dose of study treatment to death from any cause., Patient reported health-related quality of life (HRQoL):, Safety and Tolerability: incidence, nature and severity of treatment-emergent adverse events (AEs) graded according to NCI-CTCAE v6.0.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-526048-10-00 on CTIS ↗ ← All trials in the EU